#United States #Henderson #VolitionRx #epigenetics #Nu.Q® Discover

VolitionRx's Nu.Q® Discover Program: Transforming Epigenetic Testing

In a notable expansion of its innovative capabilities, VolitionRx Limited (NYSE AMERICAN: VNRX) is making waves in the epigenetic testing landscape with its Nu.Q® Discover program. As a multi-national company dedicated to advancing the science of epigenetics, VolitionRx has been making significant strides that promise to revolutionize disease detection and treatment monitoring.

Overview of the Nu.Q® Discover Program

The Nu.Q® Discover program targets an estimated total addressable market of $200 million annually. While this may appear modest compared to other segments, the program has proven to be a robust source of early revenue and showcases the versatility of the Nu.Q® platform. With a comprehensive suite of 14 state-of-the-art immunoassays, Nu.Q® Discover has established partnerships with over 20 global clients, contributing to accelerated research and development activities across several therapeutic areas.

At the heart of Nu.Q® Discover is VolitionRx's proprietary nucleosome quantification technology, which enables high-throughput epigenetic profiling. This technology is especially beneficial for large pharmaceutical and diagnostic companies aiming to enhance their development programs with unparalleled insights into biological samples and disease models. A recent study, published in the Journal of Biological Chemistry, further validates the platform, emphasizing its applicability in ongoing clinical and preclinical research.

Continued Growth and Expansion

Dr. Jasmine Kway, CEO of Volition, highlighted the increasing demand for Nu.Q® assays, especially as exploratory biomarkers in multi-national clinical trials. The influx of repeat orders from significant clients indicates a favorable trend, with revenue projections in the hundreds of thousands of dollars for ongoing longitudinal studies expected to conclude in 2026.

“Our robust pipeline and ongoing service expansion suggest sustained revenue growth for Nu.Q® Discover this year,” Dr. Kway stated. The use of Nu.Q® assays has garnered attention as a promising avenue for companion diagnostics, which could ultimately lead to valuable, long-term partnerships with pharmaceutical companies. VolitionRx is also actively exploring co-marketing partnerships to meet the rising demand seen globally.

Broad Applications Across Therapeutic Areas

Nu.Q® Discover supports the entire drug development continuum, aiding developers in assessing disease severity, monitoring treatment responses, and improving the understanding of disease mechanisms. Its applications span several pivotal areas, including oncology, neurodegenerative, and autoimmune diseases, making it one of the most versatile epigenetic solutions available.

As such, the Nu.Q® platform aligns with the industry’s pressing need for effective biomarkers that can facilitate clinical decision-making and improve patient outcomes. VolitionRx's commitment to enhancing life sciences is evident through its rigorous focus on early detection and continuous improvement of its testing capabilities.

Looking Ahead

VolitionRx anticipates substantial growth in 2025, propelled by new contracts and ongoing scientific advancements. With a commitment to innovation and a focus on unmet clinical needs, the company is actively positioning itself to lead the market in epigenetic solutions. The expertise housed within its research and development teams, concentrated in Belgium and with operational hubs in the U.S. and London, enhances its capacity to deliver cutting-edge diagnostic solutions that are not only impactful but also cost-effective.

Conclusion

In summary, the Nu.Q® Discover program represents a leap forward in epigenetic innovation, marked by VolitionRx's strategic collaborations and adherence to scientific excellence. As the landscape of disease diagnostics continues to evolve, VolitionRx’s ongoing initiatives promise to not only advance the field of epigenetics but also improve lives through earlier detection and treatment monitoring. With a solid foundation, the company is poised for transformative impacts in health care and the broader life sciences community.